Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Ownership structure
    • Financial calendar
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Remuneration

Press releases

All press releases Regulatory

Regulatory press release 2022-01-13

FDA allows review of application for market approval for Xspray Pharma’s Dasynoc™

Regulatory press release 2021-11-30

Number of shares and votes in Xspray Pharma

Press release 2021-11-18

Xspray Pharma submits application for market approval to FDA for its product candidate Dasynoc

Press release 2021-11-15

Xspray Pharma strengthens the organization with IR and Communications function

Regulatory press release 2021-11-08

Xspray Pharma completes a directed new share issue to Flerie Invest, raising approximately SEK 100 million

Regulatory press release 2021-10-26

Xspray Pharma publishes interim report Q3, January – September 2021

Regulatory press release 2021-10-25

Xspray Pharma brings forward publication of the Q3 interim report

Regulatory press release 2021-10-15

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2022

Regulatory press release 2021-10-13

Xspray Pharma has obtained results from bioequivalence studies with HyNap-Dasa ANDA and decides to focus on its improved dasatinib product, Dasynoc™

Press release 2021-08-30

All participants in Xspray Pharma studies have received their dose of generic version of dasatinib, HyNap-Dasa ANDA

Show more

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe

  • This field is for validation purposes and should be left unchanged.
  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
Xspray-logo-white

Xspray Pharma AB Scheeles väg 2 171 65 Solna

+46 (0)8 730 37 00 info@xspraypharma.com